cilgavimab/tixagevimab

{
  "id": "MLC-T-ONC-012595",
  "term": "cilgavimab/tixagevimab",
  "field": "Oncology and biomedicine",
  "definition": "A combination of two neutralizing human monoclonal antibodies cilgavimab and tixagevimab, that are isolated from convalescent patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, and directed against the spike (S) protein, that can potentially be used for passive immunization against Coronavirus disease 2019 (COVID-19). Upon administration of cilgavimab/tixagevimab, both antibodies specifically target and bind to the SARS-CoV-2 S protein, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. S protein, usually found on the surface of SARS-CoV-2, plays an essential role in the infection pathway of the SARS-CoV-2 virus.",
  "synonyms": [
    "anti-SARS-CoV-2 spike protein monoclonal antibody AZD7442",
    "AZD8895 + AZD1061",
    "AZD8895/AZD1061",
    "monoclonal antibody AZD7442"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/cilgavimab-tixagevimab/"
}